Creative Diagnostics offers the Kanamycin ELISA Kits for quantitative analysis of kanamycin residue in animal tissues (muscle and liver, etc.) and milk etc. Each of our kits goes through fit-for-purpose validation and stability testing to ensure high accuracy, sensitivity and specificity.
Creative Diagnostics offers the Pharmacokinetics ELISA Kits for the quantitation of serum protein drug levels to provide accurate pharmacokinetic (PK) data that will guide the optimization of drug dosing regimens.
Ideally a diagnostic assay for dengue should be rapid, simple, highly sensitive and specific, and preferably able to differentiate between primary and secondary infections, as well as identify the virus serotype. Creative Diagnostics offers a range of reagents designed to develop serologic assays for the early and specific diagnosis of a dengue infection.
Two highly selective anti-human Lp-PLA2 monoclonal antibodies were recently developed by Creative Diagnostics, which make possible the development of highly sensitive and rapid sandwich immunoassays.
Creative Diagnostics has just released a series of recombinant Zika virus, Alphavirus and Marburgvirus antigens for use with biopharmaceutical, clinical, and life science research applications, as well as for in-vitro diagnostic (IVD) test kit manufacturing procedures.
Creative Diagnostics is one of the first-in class global manufacturers of monoclonal and polyclonal antibodies. After a prolonged endeavor, this time we provide a powerful set of antibodies to identify plant pathogens with high affinity and minimal cross-reactivity.
Creative Diagnostics has just released a series of recombinant Ebola antigens including nuclear proteins, glycoproteins and VP40 expressed in E. coli for antibody production and immunoassay purpose.ht out several new hybridomas for production of antibodies against VSV protein.
Creative Diagnostics has brought out several new hybridomas for production of antibodies against VSV protein.
Creative Diagnostics is a pioneer of oncogene mutation specific antibodies discovery and manufacture, after years of development, there is the most comprehensive list of oncogene specific monoclonal antibodies available for both basic and clinical research.
In response to the fast merging of biotherapeutic drug field, we have now successfully developed ready-to-use Immunogenicity ELISA Kits, specially designed for detecting high affinity anti-antibody drug antibodies (ADAs) and other targets.
The entry of HIV-1 into target cells typically requires the sequential binding of the viral exterior envelope glycoprotein, gp120, to CD4 and a chemokine receptor. Creative Diagnostics released a series of baculovirus expressed HIV-1 gp120 of 4 strains (IIIB, MN, YU2, ADA) which can be used in FACS; Dot; Direct IF; Immunohistocytology. This fluorescene conjugated gp120 binds to CD4 bearing T-cells as determined by FACS.